Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer

Sjoerd Rodenhuis, Elsken van der Wall, Willem W. ten Bokkel Huinink, Jan H. Schornagel, Dick J. Richel, L. Tom Vlasveld

Research output: Contribution to journalArticlepeer-review

Abstract

Eleven patients with germ cell cancer relapsing from a complete remission and 7 patients with refractory germ cell cancer and/or an unresectable partial remission received salvage chemotherapy with one to two courses of carboplatin (800 mg/m2) and etoposide (500 mg/m2 on days 1, 3, and 5), followed b either one or two courses of carboplatin (1600 mg/m2), cyclophosphamide (6 g/d2), and thiotepa (480 mg/m2) divided over 4 days with autologous bone marrow transplantation andlor peripheral stem cell support. Eight of 11 relapsing patients (73% were salvaged (with a follow-up of 21+ to 56+ months), but only 1 of the 7 refractory patients survived (34+ months). The high-dose carboplatin-based salvage regimen is feasible and deserves further evaluation in patients relapsing from a complete remission. Even more intensive treatment strategies may be required to salvage patients who are refractory to standard doses of platinating agents.

Original languageEnglish (US)
Pages (from-to)355-362
Number of pages8
JournalCancer Investigation
Volume13
Issue number4
DOIs
StatePublished - 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer'. Together they form a unique fingerprint.

Cite this